Year To Quarter End Statement Of Income

Nxera Pharma Co., Ltd. - Filing #7272710

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
Year to quarter end statement of income
Statement of income
Net sales
6,581,000,000 JPY
5,015,000,000 JPY
Cost of sales
2,284,000,000 JPY
646,000,000 JPY
Gross profit (loss)
4,297,000,000 JPY
4,369,000,000 JPY
Selling, general and administrative expenses
Depreciation
1,403,000,000 JPY
622,000,000 JPY
Operating profit (loss)
-4,624,000,000 JPY
-335,000,000 JPY
Non-operating income
Interest income
361,000,000 JPY
132,000,000 JPY
Non-operating income
3,335,000,000 JPY
132,000,000 JPY
Non-operating expenses
Interest expenses
215,000,000 JPY
74,000,000 JPY
Non-operating expenses
256,000,000 JPY
3,098,000,000 JPY
Ordinary profit (loss)
-1,545,000,000 JPY
-3,301,000,000 JPY
Extraordinary income
Extraordinary income
3,696,000,000 JPY
7,000,000 JPY
Profit (loss) before income taxes
2,151,000,000 JPY
-3,294,000,000 JPY
Income taxes - current
7,000,000 JPY
-9,000,000 JPY
Income taxes
7,000,000 JPY
-9,000,000 JPY
Profit (loss)
2,144,000,000 JPY
2,144,000,000 JPY
2,144,000,000 JPY
-3,285,000,000 JPY
-3,285,000,000 JPY
-3,285,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.